Site Management/Investigator Payments White Papers & Case Studies

  1. Breaking Through Barriers With Integrated Trial Optimization 5/9/2025

    In today’s complex clinical trial environment, optimizing trial design requires a multidimensional strategy that balances scientific rigor with real-world constraints.

  2. Streamlining Patient Recruitment With AI–Driven Site Identification 5/1/2025

    This study highlights the use of an RWD-driven, AI-enabled recruitment models as a transformative strategy for clinical development in hard-to-recruit populations.

  3. Delivering Specialist Neurology Support 4/17/2025

    Explore a strategic approach to a Parkinson’s disease trial that leveraged a global infrastructure and multilingual workforce to provide seamless operational and clinical support.

  4. Greenphire Means GO : Streamline Your Global Clinical Trial Operations 4/16/2025

    Eliminate financial friction points in your clinical trial financial management, ensuring trials are both operationally efficient and financially transparent.

  5. Feasibility Insights In HR+/HER2 - Metastatic Breast Cancer 4/16/2025

    This case study showcases how advanced analytics were used to streamline feasibility planning for a Phase II clinical trial targeting HR+/HER2- metastatic breast cancer as a second-line treatment.

  6. Faster Trial Planning and Site Selection 4/15/2025

    Address the challenges of identifying the most suitable trial sites and investigators while optimizing feasibility planning, reducing screen failure rates, and improving patient retention.

  7. Ergomed's Solutions To The Challenges of Oncology Trials 4/15/2025

    Explore a pivotal Phase III global clinical trial investigating neoadjuvant immunotherapy for locally advanced squamous cell carcinoma of the head and neck (LA SCCHN).

  8. Engaging, Empowering & Supporting Research Sites Around The World 3/19/2025

    Accelerate trial timelines and recruitment while reducing site burden through this site network solution.

  9. Tailored Solutions For A Global Phase III Neovascular AMD Study 3/17/2025

    How did a Phase III combination study for neovascular age-related macular degeneration (AMD) overcome study complexities while expanding across 16 countries?

  10. Biotech Delivers A Superior Patient And Site Experience 3/4/2025

    To become the sponsor of choice for sites and patients in congenital hyperinsulinism clinical trials, a small biotech company prioritized delivering a superior experience while streamlining operations.